Full Press Release Details
Appoints William Monteith as Senior Vice President U.S. Manufacturing
NEW YORK--(BUSINESS WIRE)--December 10, 2018--Regulatory News:
Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a biopharmaceutical
company focused on developing immunotherapies based on gene-edited CAR
T-cells (UCART), today announced the appointment of William (Bill)
Monteith to the role of Senior Vice President U.S. Manufacturing. This
appointment follows Cellectis' plan to establish commercial
manufacturing capabilities in the U.S., which will be Bill Monteith's
responsibility, notably through the deployment of a proprietary
state-of-the-art gene-edited cell manufacturing plant for clinical and
commercial supplies of our current immuno-oncology UCART product
Bill Monteith joins Cellectis from Hitachi Chemical Advanced
Therapeutics Solutions, where he was the Chief Operating Officer and
Site General Manager for three manufacturing facilities. Bill Monteith
is based in our New York office and reports to David Sourdive, Ph.D.,
Co-founder of Cellectis and Executive Vice President Technical
"With over 35 years of experience in manufacturing, operations and
quality assurance, Bill brings his expertise and strategic capabilities
to Cellectis at a crucial time, as the company now has two
wholly-controlled product candidates being tested in clinical trials,
with more to come in 2019," said Dr. Andr Choulika, Cellectis Chief
Executive Officer. "I am confident that Bill will be a major addition to
our team and a driving force as we accelerate our transformation into a
fully-fledged biopharmaceutical company, move forward our off-the-shelf,
gene-edited CAR T-cell product candidates and continue our commitment to
a cure for cancer patients."
Bill joins Cellectis as a recognized global operations leader with deep
manufacturing expertise from his prior roles at various pharmaceutical
companies. Prior to his position at Hitachi, Bill spent over 5 years
honing his craft at Dendreon Pharmaceuticals, where he held the roles of
Vice President and General Manager and later, Executive Vice President
Technical Operations. Bill has also held positions with Sandoz
Pharmaceuticals, Shire Pharmaceuticals and Wyeth Pharmaceuticals,
playing a crucial part in their respective manufacturing processes.
"This is a pivotal time for Cellectis, as we continue clinical trials
and shift closer to product commercialization - something that will
ultimately have the potential to impact patients," noted Mr. Monteith.
"I am eager to hit the ground running and begin implementing with a team
that has already done so much to build a strong and efficient
manufacturing process, and am honored to be a part of the company that's
pioneering the allogeneic CAR T-cell space."
Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on
gene-edited T-cells (UCART). By capitalizing on its 18 years of
expertise in gene editing - built on its flagship TALEN technology and
pioneering electroporation system PulseAgile - Cellectis uses the power
of the immune system to target and eradicate cancer cells.
Using its life-science-focused, pioneering genome engineering
technologies, Cellectis' goal is to create innovative products in
multiple fields and with various target markets.
Cellectis is listed on the Nasdaq (ticker: CLLS) and on Euronext Growth
(ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Talking about gene editing? We do it. TALEN is a registered trademark
This press release contains "forward-looking" statements that are based
on our management's current expectations and assumptions and on
information currently available to management. Forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause our actual results, performance or achievements
to be materially different from any future results, performance or
achievements expressed or implied by the forward-looking statements.
Further information on the risk factors that may affect company business
and financial performance is included in Cellectis' Annual Report on
Form 20-F and the financial report (including the management report) for
the year ended December 31, 2017 and subsequent filings Cellectis makes
with the Securities Exchange Commission from time to time. Except as
required by law, we assume no obligation to update these forward-looking
statements publicly, or to update the reasons why actual results could
differ materially from those anticipated in the forward-looking
statements, even if new information becomes available in the future.
For further information, please contact:
Jennifer Moore, VP of Communications,
917-580-1088, media@cellectis.com
Caitlin Kasunich, KCSA
Strategic Communications, 212-896-1241, ckasunich@kcsa.com
Simon Harnest, VP of Corporate Strategy and
Finance, 646-385-9008, simon.harnest@cellectis.com